ArticleDiscover oncology2025
Mitochondrial energy metabolism genes as prognostic biomarkers in clear cell renal cell carcinoma via single-cell and bulk RNA sequencing analyses.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising incidence of clear cell renal cell carcinoma (ccRCC) with current treatments offering limited survival benefits and a poor prognosis. Mitochondrial abnormalities impact tumor immunity, progression, and metastasis, and the role of mitochondrial energy metabolism-related genes (MMRGs) in ccRCC remains largely unexplored. This study analyzed TCGA-KIRC, GSE159115, and GSE29609 datasets to identify differentially expressed (DE) MMRGs and their functions. It used LASSO and Cox models to select prognostic MMRGs for model building, created a nomogram (based on independent factors) in TCGA-KIRC (evaluated via calibration and ROC curves), and conducted GSEA, immune cell correlation analyses, TF-miRNA-mRNA network studies, qRT-PCR (ccRCC vs. controls), and WB (RIPA) for biomarker validation. A study of 103 DE-MMRGs highlighted their link to fatty acid metabolism and peroxisome proliferator-activated receptor (PPAR) signaling. Machine learning assessed the prognostic potential of these DE-MMRGs, which yielded a risk model based on six key biomarkers. The constructed prognostic model exhibited outstanding performance in both training and validation sets. This study also explored immune cell relevance and regulatory networks and elucidated complex mitochondrial-tumor interactions. The validation of predictive biomarker expression in clinical samples underscored their role in refining prognostic assessment and therapeutic strategies for ccRCC. In this study, six mitochondrial energy metabolism-related prognosis biomarkers (COX7B, PPARGC1B, NDUFA11, PFKFB4, NDUFV2, and NDUFA7) were screened. A risk model was developed to provide a new reference for the prognosis of ccRCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.